Search research articles
Contact Us
Filters
Showing results (1-10 of 11) with videos related to
Page
of 2
Sort By:
Alimentary Pharmacology & Therapeutics
|
July 24, 2009
Does debugging the portal system decrease pressure?
A De Gottardi, J-C Garcia-Pagan
Alimentary Pharmacology & Therapeutics
|
May 9, 2008
Review article: the modern management of portal hypertension--primary and secondary prophylaxis of variceal bleeding in cirrhotic patients
J C Garcia-Pagan, A De Gottardi, J Bosch
Shock (Augusta, Ga.)
|
April 3, 1999
Patterns of vasoregulatory gene expression in the liver response to ischemia/reperfusion and endotoxemia
N V Sonin, J C Garcia-Pagan, K Nakanishi, et al.
Alimentary Pharmacology & Therapeutics
|
June 15, 2016
Editorial: measuring inflammatory and fibrotic components of portal hypertension - a non-invasive hepatic venous pressure gradient? Authors' reply
T D Sandahl, H J Møller, S Møller, et al.
The American Review of Respiratory Disease
|
August 1, 1990
Effects of propranolol on arterial oxygenation and oxygen transport to tissues in patients with cirrhosis
A G Agusti, J Roca, J Bosch, et al.
Gut
|
February 13, 2002
Assessment of therapeutic benefit of antiviral therapy in chronic hepatitis C: is hepatic venous pressure gradient a better end point?
A K Burroughs, R Groszmann, J Bosch, et al.
Gastroenterology
|
October 1, 1996
Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure
J Bruix, A Castells, J Bosch, et al.
Hepatology (Baltimore, Md.)
|
August 8, 1998
Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems
M Guevara, P Ginès, J C Bandi, et al.
Endoscopy
|
October 1, 1995
Duodenal variceal bleeding treated with a transjugular intrahepatic portosystemic shunt
P Sort, I Elizalde, I Llach, et al.
Alimentary Pharmacology & Therapeutics
|
April 11, 2016
The macrophage activation marker sCD163 combined with markers of the Enhanced Liver Fibrosis (ELF) score predicts clinically significant portal hypertension in patients with cirrhosis
T D Sandahl, R McGrail, H J Møller, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 11) with videos related to
Sort By:
Page
of 2
Alimentary Pharmacology & Therapeutics
|
July 24, 2009
Does debugging the portal system decrease pressure?
A De Gottardi, J-C Garcia-Pagan
Alimentary Pharmacology & Therapeutics
|
May 9, 2008
Review article: the modern management of portal hypertension--primary and secondary prophylaxis of variceal bleeding in cirrhotic patients
J C Garcia-Pagan, A De Gottardi, J Bosch
Shock (Augusta, Ga.)
|
April 3, 1999
Patterns of vasoregulatory gene expression in the liver response to ischemia/reperfusion and endotoxemia
N V Sonin, J C Garcia-Pagan, K Nakanishi, et al.
Alimentary Pharmacology & Therapeutics
|
June 15, 2016
Editorial: measuring inflammatory and fibrotic components of portal hypertension - a non-invasive hepatic venous pressure gradient? Authors' reply
T D Sandahl, H J Møller, S Møller, et al.
The American Review of Respiratory Disease
|
August 1, 1990
Effects of propranolol on arterial oxygenation and oxygen transport to tissues in patients with cirrhosis
A G Agusti, J Roca, J Bosch, et al.
Gut
|
February 13, 2002
Assessment of therapeutic benefit of antiviral therapy in chronic hepatitis C: is hepatic venous pressure gradient a better end point?
A K Burroughs, R Groszmann, J Bosch, et al.
Gastroenterology
|
October 1, 1996
Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure
J Bruix, A Castells, J Bosch, et al.
Hepatology (Baltimore, Md.)
|
August 8, 1998
Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems
M Guevara, P Ginès, J C Bandi, et al.
Endoscopy
|
October 1, 1995
Duodenal variceal bleeding treated with a transjugular intrahepatic portosystemic shunt
P Sort, I Elizalde, I Llach, et al.
Alimentary Pharmacology & Therapeutics
|
April 11, 2016
The macrophage activation marker sCD163 combined with markers of the Enhanced Liver Fibrosis (ELF) score predicts clinically significant portal hypertension in patients with cirrhosis
T D Sandahl, R McGrail, H J Møller, et al.
Page
of 2